|
| Tuesday, October 28, 2025 |
|
|
康哲藥業（867.HK; 8A8.SG）簽訂眼科藥物諾適得(R)與倍優適(R)經銷協議 |
| 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，於2025年10月27日，康哲藥業通過子公司CMS VISION INTERNATIONAL MANAGEMENT LIMITED與Novartis Pharma Services AG （「諾華」）就雷珠單抗注射液（「諾適得(R)」）、布西珠單抗注射液（「倍優適(R)」）簽訂經銷協議（「協議」）。 more info >> |
|
| Monday, October 27, 2025 |
|
|
康哲药业（867.HK; 8A8.SG）签订眼科药物诺适得(R)与倍优适(R)经销协议 |
| 康哲药业控股有限公司（"康哲药业"）欣然宣布，于2025年10月27日，康哲药业通过子公司CMS VISION INTERNATIONAL MANAGEMENT LIMITED与Novartis Pharma Services AG （"诺华"）就雷珠单抗注射液（"诺适得(R)"）、布西珠单抗注射液（"倍优适(R)"）签订经销协议（"协议"）。 more info >> |
|
| Sunday, September 28, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication |
| China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the “Trial”) of ruxolitinib cream (the “Product”) in patients with mild to moderate atopic dermatitis (AD) in China. more info >> |
|
|
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication |
| China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiaries, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the "Trial") of ruxolitinib cream (the "Product") in patients with mild to moderate atopic dermatitis (AD) in China. more info >> |
|
|
康哲藥業（867.HK；8A8.SG）創新藥磷酸蘆可替尼乳膏AD中國三期臨床取得積極結果 |
| 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市，詳見康哲藥業日期為2025年4月22日發佈的公告）連同其附屬公司取得磷酸蘆可替尼乳膏（「蘆可替尼乳膏」或「產品」）輕中度特應性皮炎（AD）的中國三期藥物臨床研究（「試驗」）積極結果。 more info >> |
|
|
康哲药业（867.HK；8A8.SG）创新药磷酸芦可替尼乳膏AD中国三期临床取得积极结果 |
| 康哲药业控股有限公司（"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）连同其附属公司取得磷酸芦可替尼乳膏（"芦可替尼乳膏"或"产品"）轻中度特应性皮炎（AD）的中国三期药物临床研究（"试验"）积极结果。 more info >> |
|
| Tuesday, September 23, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively. more info >> |
|
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively. more info >> |
|
|
康哲藥業就用於破傷風被動免疫和狂犬病被動免疫的兩款創新生物製劑達成合作 |
| 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，於2025年9月22日，通過其附屬公司與重慶智翔金泰生物製藥股份有限公司（「智翔金泰」）就兩款1類治療用生物製品分別簽訂獨家合作協議（「協議」），分別為用於破傷風的被動免疫適應症的唯康度塔單抗（GR2001）注射液（「唯康度塔單抗注射液」）以及用於疑似狂犬病病毒暴露後的被動免疫適應症的斯樂韋米單抗（GR1801）注射液（「斯樂韋米單抗注射液」）。 more info >> |
|
|
康哲药业就用于破伤风被动免疫和狂犬病被动免疫的两款创新生物制剂达成合作 |
| 康哲药业控股有限公司（"康哲药业"）欣然宣布，于2025年9月22日，通过其附属公司与重庆智翔金泰生物制药股份有限公司（"智翔金泰"）就两款1类治疗用生物制品分别签订独家合作协议（"协议"），分别为用于破伤风的被动免疫适应症的唯康度塔单抗（GR2001）注射液（"唯康度塔单抗注射液"）以及用于疑似狂犬病病毒暴露后的被动免疫适应症的斯乐韦米单抗（GR1801）注射液（"斯乐韦米单抗注射液"）。 more info >> |
|
|
|
|
